Dipeptidyl Peptidase 4 Inhibitors Market Size & Share 2024 to 2032

Dipeptidyl Peptidase 4 Inhibitors Market Size

The global dipeptidyl peptidase 4 (DPP-4) inhibitors market was valued at USD 11.3 billion in 2023 and is projected to grow at a 3.5% CAGR from 2024 to 2032. This growth is primarily driven by the rising prevalence of type 2 diabetes worldwide, increasing the demand for effective treatments.

DPP-4 inhibitors have gained popularity due to their ability to regulate blood sugar levels without causing significant side effects such as weight gain or severe hypoglycemia. These medications work by preventing the breakdown of incretin hormones, thereby stimulating insulin release in response to meals, making them a preferred choice for managing type 2 diabetes.
 

Advancements in drug development and formulation have also played a significant role in the market's growth. Pharmaceutical companies are continually researching and developing new DPP-4 inhibitors that offer improved efficacy, safety, and tolerability. For instance, newer formulations with longer half-lives allow for less frequent dosing, which can enhance patient compliance. Additionally, there is a growing trend toward combination therapies that include DPP-4 inhibitors alongside other antidiabetics, providing a comprehensive approach to managing blood sugar levels in patients with type 2 diabetes. These advancements are expected to contribute to the market's continued expansion in the coming years.
 

Dipeptidyl peptidase 4 (DPP-4) inhibitors are oral medications used to treat type 2 diabetes. They work by inhibiting the DPP-4 enzyme, which deactivates incretin hormones like GLP-1 and GIP. These hormones increase insulin secretion and reduce glucagon levels after meals, helping regulate blood sugar. By blocking DPP-4, these drugs increase incretin levels, improving blood glucose control. Common DPP-4 inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin, which are often used in combination with other antidiabetic medications.
 

Dipeptidyl Peptidase 4 Inhibitors Market Trends

• The increasing global prevalence of type 2 diabetes drives the growth of the DPP-4 inhibitors market.
   
• Type 2 diabetes has become more common worldwide due to lifestyle factors such as poor diet, lack of physical activity, and rising obesity rates.
   
• For instance, according to the World Health Organization, approximately 422 million people are affected by diabetes globally, with the majority residing in low- and middle-income countries. Diabetes directly causes about 1.5 million deaths each year, and over 95% of those with diabetes have type 2.
   
• Similarly, as per the Centers for Disease Control and Prevention (CDC), 37.3 million people in the U.S. have diabetes (11.3% of the population), and 96 million adults aged 18 years or older have prediabetes (38.0% of the adult U.S. population).
   
• This rising number of diabetes cases has increased the demand for effective treatment options, including DPP-4 inhibitors, which play a crucial role in comprehensive diabetes management strategies.
   
• Additionally, the preference for oral medications supports the growth of the DPP-4 inhibitors market. Patients often favor oral DPP-4 inhibitors over injectable treatments due to their convenience and ease of use.
   
• According to the National Health and Nutrition Examination Survey (NHANES), the use of DPP-4 inhibitors among adults with type 2 diabetes in the U.S. increased from 0.5% in 2003-2006 to 10.4% in 2015-2018.
   
• The combination of efficacy, safety, and ease of use has led many patients and healthcare providers to favor DPP-4 inhibitors, supporting market growth.
   

Dipeptidyl Peptidase 4 Inhibitors Market Analysis

Based on drug type, the market is classified into sitagliptin, saxagliptin, linagliptin, alogliptin, vildagliptin, and other drug types. The sitagliptin segment dominated the DPP-4 inhibitors market with 40.4% of the market share in 2023.
 

• Sitagliptin, marketed as Januvia, is one of the first DPP-4 inhibitors approved and has a well-documented history of effectiveness and safety in lowering blood sugar levels.
   
• Additionally, it has been widely accepted in clinical practice for managing type 2 diabetes, reinforcing its status as a leading treatment option.
   
• Furthermore, its strong brand presence, supported by extensive marketing efforts, has significantly contributed to its dominant market position.
   
• Moreover, sitagliptin’s approval in multiple countries and its widespread availability contribute to its substantial market share, ensuring broad distribution and continued market dominance.
   

Based on medication type, the dipeptidyl peptidase 4 inhibitors market is segmented into branded and generic. The branded segment was valued at USD 7.9 billion in 2023.
 

• Branded DPP-4 inhibitors often come with extensive clinical trial data supporting their efficacy and safety. This robust evidence base helps build confidence among healthcare providers and patients, leading to higher market share.
   
• These types of medications have undergone rigorous regulatory scrutiny and have a long history of use, which fosters trust and preference over newer or less established options.
   
• Branded DPP-4 inhibitors benefit from well-established distribution channels that ensure wide availability across pharmacies and healthcare facilities.
   
• Owing to these factors, the branded segment dominated the market.

Learn more about the key segments shaping this market

Download Free PDF

Based on distribution channels, the DPP-4 inhibitors market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is predicted to grow at a 3.4% CAGR during the analysis period.
 

• Hospital pharmacies play a critical role in providing medications for patients with complex or advanced diabetes, often requiring hospitalization for intensive management.
   
• The expansion of healthcare infrastructure, especially in emerging markets, further enhances access to these treatments through hospitals, where patients receive personalized care and regular monitoring, driving demand for DPP-4 inhibitors in hospital settings.
   
• Additionally, hospitals often collaborate with pharmaceutical companies to ensure a steady supply of medications, making them a reliable channel for DPP-4 inhibitor distribution.
   
• As hospitals increasingly serve as centers for diabetes care, their pharmacies are expected to see rising demand for DPP-4 inhibitors, leading to projected growth during the analysis period.

The North America dipeptidyl peptidase 4 inhibitors market accounted for USD 4.6 billion in 2023 and is expected to witness growth at a 3.4% CAGR during the analysis period.
 

• The increasing prevalence of type 2 diabetes in the region drives the demand for DPP-4 inhibitors, as they are an effective treatment option for managing blood sugar levels.
   
• Rising obesity rates and sedentary lifestyles in the U.S. and Canada further contribute to the growing diabetes burden, increasing the demand for antidiabetic medications, including DPP-4 inhibitors.
   
• Additionally, North America's well-established healthcare infrastructure, advanced medical research capabilities, and high healthcare expenditure further support market growth.
   

The U.S. DPP-4 inhibitors market is expected to reach USD 5.6 billion by 2032 with a 3.3% CAGR.
 

• According to the CDC, in 2021, 38.4 million people, or 11.6% of the U.S. population, had diabetes. This high prevalence, particularly of type 2 diabetes, underscores the growing need for medications that help manage blood sugar levels.
   
• DPP-4 inhibitors are widely used due to their effectiveness in lowering glucose levels without causing significant hypoglycemia, making them a preferred option for many patients.
   
• Furthermore, favorable regulatory environments, along with the widespread availability of these drugs through hospital pharmacies and retail outlets, further boost market growth.
   

The China DPP-4 inhibitors market is anticipated to grow at a remarkable rate over the forecast period.
 

• China’s growing healthcare infrastructure and increasing healthcare spending contribute to the market’s growth. As the Chinese government continues to prioritize healthcare reforms, access to innovative diabetes treatments, including DPP-4 inhibitors, is becoming more widespread.
   
• Additionally, local and global pharmaceutical companies are investing heavily in expanding their presence in China, driving awareness and adoption of DPP-4 inhibitors.
   
• Increasing partnerships, regulatory approvals, and broader insurance coverage for diabetes medications are further expected to support the market's strong growth trajectory over the forecast period.
   

India is predicted to highlight significant growth in the DPP-4 inhibitors market.
 

• According to the World Health Organization, an estimated 77 million people in India over the age of 18 suffer from type 2 diabetes, with nearly 25 million individuals being prediabetic and at higher risk of developing diabetes in the near future.
   
• This rising prevalence of diabetes and prediabetes in India is a major public health concern, driven by factors such as sedentary lifestyles, unhealthy diets, and increasing rates of obesity.
   
• As a result, the country is predicted to highlight significant growth in the DPP-4 inhibitors market, driven by the increasing demand for more effective medications to control blood sugar levels, growing awareness of diabetes treatment options, and the expanding availability of DPP-4 inhibitors in healthcare settings.
   

Dipeptidyl Peptidase 4 Inhibitors Market Share

The market is characterized by a highly competitive landscape, with key players vying for market share through innovation and strategic initiatives. Leading companies such as Merck & Co., Inc., AstraZeneca plc, Eli Lilly and Company, Novartis AG, and Sanofi hold significant market shares due to their well-established diabetes treatment portfolios and strong global presence. These firms are highly competitive in advancing research and development to innovate new DPP-4 inhibitors and expand their therapeutic uses.
 

Dipeptidyl Peptidase 4 Inhibitors Market Companies

Prominent players operating in the dipeptidyl peptidase 4 inhibitors industry include:

• AstraZeneca plc
• Bristol Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Eli Lilly and Company
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Pfizer, Inc.
• Takeda Pharmaceuticals Company Limited
• Sanofi
• Sanwa Kagaku Kenkyusho Co., Ltd.
   

Dipeptidyl Peptidase 4 Inhibitors Industry News:

• In October 2023, Zydus Lifesciences announced the approval of its New Drug Application (NDA) for ZITUVIO (sitagliptin) tablets in 25 mg, 50 mg, and 100 mg strengths by the U.S. Food and Drug Administration (FDA). This approval helped the company expand its product offerings.
   

The dipeptidyl peptidase 4 inhibitors market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Sitagliptin
• Saxagliptin
• Linagliptin
• Alogliptin
• Vildagliptin
• Other drug types

Market, By Medication Type

• Branded
• Generic

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa